Stock ILM1 MEDIOS AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Medios AG

Equities

ILM1

DE000A1MMCC8

Real-time Estimate Tradegate
Other stock markets
 04:17:22 2024-04-26 am EDT 		5-day change 1st Jan Change
14.1 EUR 0.00% Intraday chart for Medios AG -2.23% -11.48%
Mar. 27 Medios AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 18 Medios AG Provides Earnings Guidance for the Year 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The stock, which is currently worth 2024 to 0.25 times its sales, is clearly overvalued in comparison with peers.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MEDIOS AG Stock Medios AG
-11.48% 360M -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.58% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.95% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.25% 233B
B+
NOVARTIS AG Stock Novartis AG
+5.40% 201B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.31% 193B
A+
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 143B
C+
AMGEN INC. Stock Amgen Inc.
-6.47% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ILM1 Stock
  4. Ratings Medios AG